Early non-invasive diagnosis of cervical cancer: Beyond Pap smears and human papilloma virus (HPV) testing

Cancer Biomarkers

Volumn 1, Issue 2-3, 2005, Pages 183-191

  Mathur, Subbi P ^a   Mathur, Rajesh S ^a   Creasman, Willaim T ^a   Underwood, Paul B ^a   Kohler, Matthew ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IGFBP3 PROTEIN, HUMAN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ARTICLE; BIOLOGICAL MODEL; BLOOD; EARLY DIAGNOSIS; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; METHODOLOGY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIRUS INFECTION;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DIAGNOSTIC TECHNIQUES, OBSTETRICAL AND GYNECOLOGICAL; EARLY DIAGNOSIS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MODELS, BIOLOGICAL; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 34748822163     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2005-12-306     Document Type: Article

References (39)

1. S.S. Devesa, D.J. Grauman, W.J. Blot, G.A. Pennello, R.N. Hoover and J.F. Fraumeni, Jr., Atlas of cancer mortality in the United States: 1950-1994, Washington [DC]: US Govt Print Off; NIH Publ No. 99-4564, 1999.
2. S.L. Parker, T. Tong and S. Bolden, Cancer Statistics 1997, CA Cancer J. Clin. 47 (1997), 1-27.
3. P.L. Blomfield, R.J. Lancashire and C.B.J. Woodman, Can women at risk of cervical abnormality be identified? Brit J Obstet Gyn 105 (1998), 486-492.
4. D.R. Genest, B. Dean, K.R. Lee, E. Sheets, C.P. Crum and E.S. Cibas, Qualifying the cytologic diagnosis of "Atypical squamous cells of undetermined significance" affects the predictive value of a squamous intraepithelial lesion on subsequent biopsy, Arch Pathol Lab Med 122 (1998), 338-341.
5. J.J. O'Leary, R.J. Landers, M. Crowley, I. Healy, W.F. Kealy, J. Hogan, C. Cullinane, P. Kelehan and C.T. Doyle, Genotypic mapping of HPV and assessment of EBV prevalence in endocervical lesions, J. Clin. Pathol. 50 (1997), 904-910.
6. R.C. Jaworski, Endocervical glandular dysplasia, adenocarcinoma in situ and early invasive [microinvasive] adenocarcinoma of the uterine cervix, Semin. Diagn. Pathol. 7 (1990), 190-204.
7. A. Berchuck and K.J. Rodabaugh. Role of Oncogene and Tumor Suppressor Gene Alterations in Cervical Carcinogenesis, in: Cervical Cancer and Preinvasive Neoplasia, S.C. Rubin andW.J. Hoskins, eds, Lippincott-Raven Publishers, Philadelphia, PA, 1996, pp. 49-57.
8. R.D. Burk, Y. Gloria, F. Ho, L. Beardsley, M. Lempa, M. Peters and R. Bierman, Sexual behavior and partner characteristics are the predominant risk factors for genital human Papillomavirus infection in young women, J. Infect. Dis. 174 (1996), 679-689.
9. I.M. Sasson, H.J. Haley, D. Hoffman, E.L. Wynder, D. Hellberg and S. Nilsson, Cigarette smoking and neoplasia of the uterine cervix, N. Engl. J. Med. 312 (1985), 315-316.
10. J.L. Daling, M.M. Madeleine, B. Mcknight, J.J. Carter, G.C. Wipf, R. Ashley, S.M. Schwartz, A.M. Beckman, M.E. Hagensee, M.T. Mandelson and D.A. Galloway, The relationship of human Papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type-2 infection, Cancer Epidemiology, Biomarkers and Prevention 5 (1996), 541-548.
11. M.L. Slattery, L.M. Robinson, K.L. Schuman, T.K. French, T.M. Abbott, J.C.Overall and J.W. Gardner, Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer, JAMA 261 (1989), 1593-1644.
12. W. Winkelstein, Smoking and cancer of the uterine cervix: a hypothesis, Am J. Epidemiol 106 (1977), 257-259.
13. E.M. Rakowicz-Szulczynska, D.G. McIntosh and M.L. Smith, Growth factor mediated mechanisms of nicotine-dependent carcinogenesis, Carcinogenesis 15 (1994). 1839-1846.
14. M. Rakowicz-Szulczynska, D.G. McIntosh and M.L. Smith, PGDF AA as mediator in nicotine dependent carcinogenesis, Carcinogenesis 17 (1996), 1813-1818.
15. B. Ozanne, C.S. Richards, F. Hendler, D. Burns and B. Gusterson, Over-expression of EGF receptor in a hallmark of squamous cell carcinomas, J. Pathol. 149 (1986), 9-14.
16. D. Pfeiffer, J. Spranger, M. Al-Deiri, E. Kimmig, A. Fisseler-Eckhoff, P. Scheidel, H. Schatz, A. Jensen and A. Pfeiffer, mRNA expression of ligands of the epidermal-growth-factorreceptor in the uterus, Int J Cancer 72 (1997), 581-586.
17. W.J. Gullick, J.J. Marsden, N. Whittle, B. Ward, L. Bobrow and M.D. Waterfield, Expression of epidermal growth factor receptors on human cervical, ovarian and vulval carcinomas, Cancer Res 46 (1986), 285-292.
18. R.S. Mathur, S.P. Mathur and R.C. Young, Up-regulation of Epidermal Growth Factor Receptors [EGF-R] by Nicotine in Cervical Cancer Cell Lines: This Effect is mediated by EGF, Am. J. Reprod. Imm. 44 (2000), 114-120.
19. S.P. Mathur, R.S. Mathur and R.C. Young, Human Papilloma virus [HPV] protein E6/E7 and epidermal growth factor receptor [EGF-R] levels in women with cervical cancer and CIN, Am. J. Reprod. Immunol. 46 (2001), 280-287.
20. R.S. Mathur, S.P. Mathur, R. Schumann and R.C. Young, IGFII production parallels EGF-receptor [EGF-R] up-regulation by EGF in a cervical cancer cell line [HT-33], Endocrine Society Meeting, June, 1998.
21. S.P. Mathur, C.P. Landen, S.M. Datta, M.C. Hoffmann, R.S. Mathur and R.C. Young, Insulin-like Growth Factor II Levels in Gynecological Cancers, Am J. Rep Immunol. 49 (2003), 113-119.
22. S.P. Mathur, R.S. Mathur and R.C. Young, Cervical Epidermal Growth Factor Receptor [EGF-R] and insulin-like growth factor II [IGF-II] Levels in Women with Cervical Cancer and Cervical Intraepithelial Neoplasia [CIN], Am. J. Reprod. Immunol. 44 (2000) 222-230.
23. S.P. Mathur, R.S. Mathur, P.B. Underwood, M.F. Kohler and W.T. Creasman, Circulating Levels of Insulin-like Growth Factor-II and IGF-binding Protein 3 in Cervical Cancer, Gyn. Oncology 91 (2004), 486-493.
24. S.J. Moschos and C.S. Mantzoros, The role of the IGF system in cancer: from basic to clinical studies and clinical applications, Oncology 63 (2002), 317-332.
25. G. Furstenberger and H.J. Senn, Insulin-like Growth Factors and Cancer, Lancet Oncology 3 (2002), 298-302.
26. R. Palmqvist, G. Hallmans, S. Rinaldi, C. Biessy, R. Stenling, E. Riboli and R. Kaaks, Plasma insulin-like growth factor I, insulin-like growth factor binding protein 3 and risk of colorectal cancer: a prospective study in northern Sweden, Gut 50 (2002), 642-646.
27. E. Giovannucci, M.N. Pollak, E.A. Platz, W.C. Willett, M.J. Stampfer, N. Majeed, G.A. Colditz, F.E. Speizer and S.E. Hankinson, A prospective study of plasma insulin-like growth factor I and binding protein3 and risk of colorectal neoplasia in women, Cancer Epidemiology, Biomarkers and Prevention 9 (2000), 345-349.
28. R.A. Krajcik, N.D. Borofsky, S. Massardo and N. Orentreich, Insulin-like growth factor I [IGF-I], IGF-binding proteins and breast cancer, Cancer Epidemiology, Biomarkers and Prevention 11 (2002), 1566-1573.
29. S.E. Hankinson, W.C. Willett and G.A. Colditz, Circulating concentrations of insulin-like growth factor I and risk of breast cancer, Lancet 351 (1998), 1393-1396.
30. J.P. Peyrat, J. Bonneterre and B. Hecquet, Plasma insulin-like growth factor I [IGF-I] concentrations in human breast cancer, Eur. J. Cancer 29 (1993), 492-497.
31. S.I. Helle and P.E. Lonning, Insulin-like growth factors in breast cancer, Acta Oncologica 35(Suppl. 5) (1996), 19-22.
32. M.R. Spitz, M.J. Barnett, G.E. Goodman, M.D. Thornquist, X. Wu and M. Pillak, Serum Insulin-like growth factor [IGF] and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiology, Biomarkers and Prevention 11 (2002), 1413-1418.
33. A. Lukanova, E. Lundin, P. Toniolo, A. Micheli, A. Akhmedkhanov, S. Rinaldi, P. Muti, P. Lenner, C. Biessy, V. Krogh, A. Zeleniuch-Jacquotte, F. Berrino, G. Hallmans, E. Riboli and R. Kaaks, Circulating levels of insulin-like growth factor I and risk of ovarian cancer, International Journal of Cancer 101 (2002), 549-554.
34. N.L. Ge and S. Rudikoff, Insulin-like growth factor I is a dual effector of multiple myeloma cell growth, Blood 96 (2000), 2856-28561.
35. K. Szeeshazi, A.V. Schally, K. Groot, P. Armatis, F. Hebert and G. Halmos, Antagnoists of growth hormone-releasing hormone [GH-RH] inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors, European Journal of Cancer 36 (2000), 128-136.
36. M. Korc, Role of growth factors in pancreatic cancer, Surgical Oncology Clinics of North America 7 (1998), 25-41.
37. B.M. Brennan, M. Gill, L. Pennells, O.B. Eden, A.G. Thomas and P.E. Clayton, Insulin-like growth factor I, IGF-binding protein 3 and IGFBP protease activity: in relation to anthropometric indices in solid tumors or leukemia, Archives of Disease in Childhood 80 (1999), 226-230.
38. R.C. Baxter, J.L. Martin and V.A. Beniac, High molecular weight insulin-like growth factor binding protein complex, J. Biol. Chem. 264 (1989), 11843-11848.
39. J. Hong, G. Zhang, F. Dong and M.M. Rechler, Insulin-like growth factor [IGF]-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells, J. Biol. Chem. 277 (2002), 10489-10497.